These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 38030173)
1. Correlation of Intra-tumoral and Peripheral PD-1/PD-L1 Immunity in Head and Neck Cancer. Idel C; Ribbat-Idel J; VON Bernuth A; Fleckner J; Rades D; Kirfel J; Sailer V; Plötze-Martin K; Bruchhage KL; Pries R Anticancer Res; 2023 Dec; 43(12):5349-5358. PubMed ID: 38030173 [TBL] [Abstract][Full Text] [Related]
2. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843 [TBL] [Abstract][Full Text] [Related]
3. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation. Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199 [TBL] [Abstract][Full Text] [Related]
4. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma. Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437 [TBL] [Abstract][Full Text] [Related]
5. PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma. Su NW; Dai SH; Hsu K; Chang KM; Ko CC; Kao CW; Chang YF; Chen CG Cancer Immunol Immunother; 2024 Jan; 73(1):3. PubMed ID: 38175307 [TBL] [Abstract][Full Text] [Related]
6. Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs. Ahmadvand S; Norouzi LA; Mohammadi Y; Safaei A; Khademi B; Motiee-Langroudi M; Ghaderi A BMC Immunol; 2024 Jan; 25(1):7. PubMed ID: 38229027 [TBL] [Abstract][Full Text] [Related]
7. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325 [TBL] [Abstract][Full Text] [Related]
8. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas. Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. Strati A; Koutsodontis G; Papaxoinis G; Angelidis I; Zavridou M; Economopoulou P; Kotsantis I; Avgeris M; Mazel M; Perisanidis C; Sasaki C; Alix-Panabières C; Lianidou E; Psyrri A Ann Oncol; 2017 Aug; 28(8):1923-1933. PubMed ID: 28838214 [TBL] [Abstract][Full Text] [Related]
10. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation. Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma. Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025 [TBL] [Abstract][Full Text] [Related]
12. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer. Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL Front Immunol; 2020; 11():1721. PubMed ID: 33072064 [TBL] [Abstract][Full Text] [Related]
13. Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. Shafi S; Aung TN; Xirou V; Gavrielatou N; Vathiotis IA; Fernandez A; Moutafi M; Yaghoobi V; Herbst RS; Liu LN; Langermann S; Rimm DL Lab Invest; 2022 Oct; 102(10):1143-1149. PubMed ID: 35581307 [TBL] [Abstract][Full Text] [Related]
14. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178 [TBL] [Abstract][Full Text] [Related]
15. Partial recovery of peripheral blood monocyte subsets in head and neck squamous cell carcinoma patients upon radio(chemo)therapy is associated with decreased plasma CXCL11. Idel C; Fleckner J; Plötze-Martin K; Werner L; Rades D; Theodoraki MN; Hofmann L; Huber D; Leichtle A; Hoffmann TK; Bruchhage KL; Pries R BMC Cancer; 2024 Apr; 24(1):459. PubMed ID: 38609887 [TBL] [Abstract][Full Text] [Related]
16. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy. Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445 [TBL] [Abstract][Full Text] [Related]
17. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis. Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X Front Immunol; 2021; 12():645170. PubMed ID: 33897693 [TBL] [Abstract][Full Text] [Related]
18. Association between spatial distribution of leukocyte subsets and clinical presentation of head and neck squamous cell carcinoma. Netzer C; von Arps-Aubert V; Mačinković I; von der Grün J; Küffer S; Ströbel P; von Knethen A; Weigert A; Beutner D Front Immunol; 2023; 14():1240394. PubMed ID: 38322012 [TBL] [Abstract][Full Text] [Related]
19. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials. Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of thioredoxin reductase 1 causes ferroptosis while potentiating anti-PD-1 efficacy in head and neck cancer. Hsieh MS; Ling HH; Setiawan SA; Hardianti MS; Fong IH; Yeh CT; Chen JH Chem Biol Interact; 2024 May; 395():111004. PubMed ID: 38636790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]